OnKure Therapeutics (OKUR) Competitors $18.42 -0.58 (-3.05%) (As of 10/11/2024 ET) Add Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsTrends OKUR vs. NKTR, AMRN, NBTX, IMMP, AMLX, MRSN, MGNX, GOSS, ENTA, and CRBPShould you be buying OnKure Therapeutics stock or one of its competitors? The main competitors of OnKure Therapeutics include Nektar Therapeutics (NKTR), Amarin (AMRN), Nanobiotix (NBTX), Immutep (IMMP), Amylyx Pharmaceuticals (AMLX), Mersana Therapeutics (MRSN), MacroGenics (MGNX), Gossamer Bio (GOSS), Enanta Pharmaceuticals (ENTA), and Corbus Pharmaceuticals (CRBP). These companies are all part of the "pharmaceutical preparations" industry. OnKure Therapeutics vs. Nektar Therapeutics Amarin Nanobiotix Immutep Amylyx Pharmaceuticals Mersana Therapeutics MacroGenics Gossamer Bio Enanta Pharmaceuticals Corbus Pharmaceuticals Nektar Therapeutics (NASDAQ:NKTR) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability. Do analysts recommend NKTR or OKUR? Nektar Therapeutics presently has a consensus target price of $2.33, indicating a potential upside of 71.57%. OnKure Therapeutics has a consensus target price of $35.00, indicating a potential upside of 90.01%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than Nektar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do institutionals and insiders hold more shares of NKTR or OKUR? 75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 3.7% of Nektar Therapeutics shares are held by company insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is NKTR or OKUR more profitable? OnKure Therapeutics has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -190.09%. OnKure Therapeutics' return on equity of -62.52% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nektar Therapeutics-190.09% -133.64% -42.03% OnKure Therapeutics N/A -62.52%-56.36% Does the MarketBeat Community prefer NKTR or OKUR? Nektar Therapeutics received 628 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 70.67% of users gave Nektar Therapeutics an outperform vote. CompanyUnderperformOutperformNektar TherapeuticsOutperform Votes62970.67% Underperform Votes26129.33% OnKure TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes Does the media prefer NKTR or OKUR? In the previous week, Nektar Therapeutics had 4 more articles in the media than OnKure Therapeutics. MarketBeat recorded 6 mentions for Nektar Therapeutics and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.50 beat Nektar Therapeutics' score of 0.97 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Nektar Therapeutics Positive OnKure Therapeutics Very Positive Which has stronger earnings and valuation, NKTR or OKUR? OnKure Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNektar Therapeutics$93.16M2.69-$276.06M-$0.92-1.48OnKure TherapeuticsN/AN/A-$77.39M-$16.80-1.10 Which has more risk & volatility, NKTR or OKUR? Nektar Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. SummaryOnKure Therapeutics beats Nektar Therapeutics on 11 of the 18 factors compared between the two stocks. Ad Brownstone ResearchAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowClick here to see why Get OnKure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OKUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKUR vs. The Competition Export to ExcelMetricOnKure TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.52M$7.35B$5.51B$8.47BDividend YieldN/A7.80%4.42%4.14%P/E Ratio-1.1016.48116.9218.04Price / SalesN/A245.431,241.2769.81Price / CashN/A45.7739.5533.52Price / Book0.695.424.704.55Net Income-$77.39M$153.03M$120.96M$226.71M7 Day PerformanceN/A2.83%0.54%2.38%1 Month PerformanceN/A20.27%17.12%13.46%1 Year PerformanceN/A24.21%29.30%23.40% OnKure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKUROnKure Therapeutics3.6486 of 5 stars$18.42-3.1%$35.00+90.0%N/A$61.52MN/A-1.10N/AAnalyst ForecastPositive NewsGap DownHigh Trading VolumeNKTRNektar Therapeutics4.4411 of 5 stars$1.29-0.8%$2.33+80.9%+160.2%$239.30M$90.12M-1.43220Gap DownAMRNAmarin2.4752 of 5 stars$0.58flat$1.00+71.6%-25.1%$238.19M$306.91M-7.29360Positive NewsNBTXNanobiotix3.2146 of 5 stars$5.00-1.0%$11.50+130.0%-28.7%$238.02M$39.18M0.00100Short Interest ↓Positive NewsIMMPImmutep1.6756 of 5 stars$2.08+4.0%$8.00+285.5%+14.4%$237.77M$5.14M0.002,021News CoverageGap UpAMLXAmylyx Pharmaceuticals3.2647 of 5 stars$3.46+2.1%$17.60+408.7%-80.8%$235.30M$298.76M-1.41200MRSNMersana Therapeutics4.4785 of 5 stars$1.90+1.1%$6.00+215.8%+34.0%$230.63M$36.85M-2.18150Gap DownMGNXMacroGenics4.4887 of 5 stars$3.74+2.5%$8.11+116.9%-18.5%$228.94M$58.75M-1.70430Positive NewsGOSSGossamer Bio4.352 of 5 stars$0.98-3.0%$9.20+835.2%+44.9%$228.49MN/A-2.52180ENTAEnanta Pharmaceuticals4.0742 of 5 stars$10.63-0.7%$20.00+88.1%+11.9%$226.93M$79.20M-1.95160Analyst ForecastNews CoverageCRBPCorbus Pharmaceuticals4.6659 of 5 stars$18.32-1.1%$65.86+259.5%+209.4%$223.05M$880,000.00-3.1540Short Interest ↑Positive News Related Companies and Tools Related Companies: Nektar Therapeutics Alternatives Amarin Alternatives Nanobiotix Alternatives Immutep Alternatives Amylyx Pharmaceuticals Alternatives Mersana Therapeutics Alternatives MacroGenics Alternatives Gossamer Bio Alternatives Enanta Pharmaceuticals Alternatives Corbus Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OKUR) was last updated on 10/12/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredThe Crypto Whisperer Just Sounded the AlarmThe 2024 Altcoin Eruption is Almost Here (Get in by Nov. 4) In late 2020, Ian King urged his readers to tak...Banyan Hill Publishing | SponsoredDon’t Miss Out: Elon’s Game-Changing InventionWhen you click here you'll discover what Elon Musk's newest invention can do… And how it works… You migh...InvestorPlace | SponsoredMust-backed energy grid could save us allElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored[SHOCKING] Crypto Document Leak…A shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
